This HTML5 document contains 167 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n9http://dx.doi.org/10.3324/
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q42335813
rdf:type
wikibase:Item
schema:description
vedecký článok vetenskaplig artikel teaduslik artikkel article scientific videnskabelig artikel scientific article published on 18 August 2016 სამეცნიერო სტატია wetenschappelijk artikel artikulong pang-agham vitenskapelig artikkel artigo científico 2016年論文 2016年論文 2016年论文 مقالة علمية نشرت في 18 أغسطس 2016 scienca artikolo vitskapeleg artikkel 2016年の論文 artykuł naukowy บทความทางวิทยาศาสตร์ 2016 nî lūn-bûn artikel ilmiah 2016年论文 wissenschaftlicher Artikel scientific article published on 18 August 2016 articolo scientifico artigo científico 2016年論文 tieteellinen artikkeli artículu científicu espublizáu en 2016 2016年论文 научни чланак articol științific научна статия article científic artigo científico ১৮ আগস্ট ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי 2016年论文 2016年論文 2016年论文 tudományos cikk artikull shkencor наукова стаття, опублікована в серпні 2016 2016年論文 мақолаи илмӣ 2016년 논문 επιστημονικό άρθρο bài báo khoa học naučni članak научни чланак vědecký článek artículo científico publicado en 2016 article scientifique 2016年论文 bilimsel makale научная статья scientific article published on 18 August 2016
p:P577
wds:Q42335813-DFEB46C6-55E5-4EDB-B340-29A7FBFD4826
wdt:P577
2016-08-18T00:00:00Z
p:P2860
wds:Q42335813-B878F9E0-CF0E-4048-A0AE-8FA1ADF4E138 wds:Q42335813-C91CB33E-8DC2-4477-A45B-0C59D743A998 wds:Q42335813-E9A68069-5E10-4085-9DA7-134A52FE6326 wds:Q42335813-EB8832C2-4620-4AED-82AE-7541E83D5AEB wds:Q42335813-ED91DC55-3D31-4511-91C9-389A8D0EEB01 wds:Q42335813-EF8FE0EA-4C06-4996-A10F-361C4D6C22B4 wds:Q42335813-5AECB61D-3D63-422F-B2AF-3A6247D83D1D wds:Q42335813-70D477C3-23A6-46BA-89E0-9C9643679000 wds:Q42335813-7D61DF82-9732-4FA0-9EA7-971EAF9BDA2B wds:Q42335813-ACFED563-FC24-4432-A1E1-E8AF2DCFAD83 wds:Q42335813-14822DE8-A39F-4120-BA34-BE2295018F50 wds:Q42335813-177562C7-5FE1-495A-919D-1569D4F19F56 wds:Q42335813-2D69F651-E589-42C6-BBAF-BD31B44FD651 wds:Q42335813-38ACC20E-E384-4C26-B6BC-3DFC57ACF80E wds:Q42335813-4274878D-25D6-4B68-9FF2-EF5D78B59F4C
wdt:P2860
wd:Q37970946 wd:Q33696008 wd:Q33422017 wd:Q34603644 wd:Q42875323 wd:Q34226021 wd:Q33387698 wd:Q52868558 wd:Q36936514 wd:Q35800851 wd:Q33416427 wd:Q43143104 wd:Q53127020 wd:Q33394981 wd:Q40373720
p:P2093
wds:Q42335813-0D12C971-3921-4E9B-9BB9-314A9EA038AC wds:Q42335813-526E208A-5915-4B33-BBFB-EA5DDDAE0918 wds:Q42335813-96911E4C-EF91-4030-AE80-1AEED56E3504
wdt:P2093
Anna Jauch Christina Kunz Igor W Blau
rdfs:label
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
skos:prefLabel
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
schema:name
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
p:P50
wds:Q42335813-ED343AC9-5253-4CEF-89EF-C5984D5DF6CB wds:Q42335813-EA599E39-B5B3-4660-BAC7-E9847B2D9518 wds:Q42335813-CA2FBCBA-EBBD-4C5F-9255-0F82E7CCA92C wds:Q42335813-D422F624-2F93-495F-87E3-C9CD807E914E wds:Q42335813-AE3EAC30-6AE1-4970-9711-A47FEE372804 wds:Q42335813-B3EC1AAD-165F-4052-81B7-54AFC68C8C4B wds:Q42335813-BA3672DB-AA3C-4676-A20B-4DCF738974EF wds:Q42335813-F86D4EFA-DCC5-4D0C-8A3B-5679709AE98E wds:Q42335813-F89F1AA2-DEDB-42A1-9BBF-BA4CA478BA6A wds:Q42335813-3BE8A4D7-FF98-46FB-B6C0-E0D15EB01A19 wds:Q42335813-27419A35-9449-44CB-B3C6-32EAE7AE5D3E wds:Q42335813-0D6F539B-9BC9-4D26-B756-BA25B3021493 wds:Q42335813-00B5666A-8BC8-4BA5-BB6D-76E8ED9DFE1C wds:Q42335813-982E26E8-DDF6-465D-AFE7-B92BDE665037 wds:Q42335813-A32FA506-AE49-42BC-B143-C194E675476F wds:Q42335813-93C8A50E-B4F4-47F1-8EB9-2EF6974E8452 wds:Q42335813-94321ECB-75DD-4A4C-8DDF-47D1C55D3A9B wds:Q42335813-980A0977-344F-46F6-94E3-5DF47134F359 wds:Q42335813-896B0211-F78E-4E23-932D-F5D923746457 wds:Q42335813-5CBEC147-A0CA-4452-9FAB-E7CAF446FC83
wdt:P50
wd:Q57159225 wd:Q114426806 wd:Q114778035 wd:Q88396694 wd:Q98618641 wd:Q117223796 wd:Q87639824 wd:Q96475433 wd:Q23061917 wd:Q57206982 wd:Q117223793 wd:Q117223792 wd:Q117223795 wd:Q114518411 wd:Q117223785 wd:Q90260451 wd:Q91521823 wd:Q117223794 wd:Q95829739 wd:Q86423503
p:P1476
wds:Q42335813-37E125B8-EAC5-46E6-A948-259BFB2E94B9
wdt:P1476
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial
p:P304
wds:Q42335813-03D94CA2-BBB1-4893-8B42-7DC975FC43AF
wdt:P304
e485-e487
p:P31
wds:Q42335813-FDD62901-238F-401B-81B1-B318D071DBF5
wdt:P31
wd:Q13442814
p:P921
wds:Q42335813-22AD6E69-60E4-49F2-9484-F2FD3C19C844 wds:Q42335813-E62A8467-A539-4DB2-888E-95B358D59731
wdt:P921
wd:Q42824827 wd:Q945238
p:P698
wds:Q42335813-8D80B0C0-1652-4CC1-ABF8-E102E7A5C926
wdtn:P698
n12:27540135
wdt:P698
27540135
p:P1433
wds:Q42335813-F7A71995-1841-41FD-94EB-7CB1C27F86CE
wdt:P1433
wd:Q5638209
p:P433
wds:Q42335813-F5BA0D3D-8BA7-42F2-A183-4216C0A39116
p:P478
wds:Q42335813-A2F0C8E7-2A80-4A6B-909D-3A3D0A1FB5A2
wdt:P433
12
wdt:P478
101
p:P356
wds:Q42335813-652D7C28-C9E5-4B2B-A967-E70AD21E0B3C
wdtn:P356
n9:HAEMATOL.2016.151266
wdt:P356
10.3324/HAEMATOL.2016.151266
p:P932
wds:Q42335813-6EAF5585-90DE-4C8E-9BBB-ABAEF334D544
wdt:P932
5479613